全文获取类型
收费全文 | 181603篇 |
免费 | 1285篇 |
国内免费 | 64篇 |
专业分类
耳鼻咽喉 | 1195篇 |
儿科学 | 6697篇 |
妇产科学 | 3033篇 |
基础医学 | 17227篇 |
口腔科学 | 1747篇 |
临床医学 | 12689篇 |
内科学 | 32177篇 |
皮肤病学 | 885篇 |
神经病学 | 17157篇 |
特种医学 | 9123篇 |
外科学 | 29937篇 |
综合类 | 2337篇 |
一般理论 | 1篇 |
预防医学 | 18200篇 |
眼科学 | 2930篇 |
药学 | 9836篇 |
中国医学 | 631篇 |
肿瘤学 | 17150篇 |
出版年
2023年 | 52篇 |
2022年 | 119篇 |
2021年 | 204篇 |
2020年 | 108篇 |
2019年 | 150篇 |
2018年 | 22061篇 |
2017年 | 17467篇 |
2016年 | 19632篇 |
2015年 | 1050篇 |
2014年 | 983篇 |
2013年 | 977篇 |
2012年 | 7364篇 |
2011年 | 21357篇 |
2010年 | 19036篇 |
2009年 | 11687篇 |
2008年 | 19811篇 |
2007年 | 22007篇 |
2006年 | 866篇 |
2005年 | 2492篇 |
2004年 | 3715篇 |
2003年 | 4666篇 |
2002年 | 2802篇 |
2001年 | 405篇 |
2000年 | 564篇 |
1999年 | 298篇 |
1998年 | 286篇 |
1997年 | 266篇 |
1996年 | 146篇 |
1995年 | 167篇 |
1994年 | 153篇 |
1993年 | 113篇 |
1992年 | 156篇 |
1991年 | 197篇 |
1990年 | 203篇 |
1989年 | 149篇 |
1988年 | 123篇 |
1987年 | 108篇 |
1986年 | 82篇 |
1985年 | 84篇 |
1984年 | 75篇 |
1983年 | 64篇 |
1982年 | 46篇 |
1980年 | 51篇 |
1974年 | 31篇 |
1970年 | 31篇 |
1969年 | 33篇 |
1938年 | 60篇 |
1934年 | 30篇 |
1932年 | 56篇 |
1930年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Hypertension and hypercholesterolemia are frequently associated, and their treatment is proven to reduce cardiovascular risk.
Current guidelines on cardiovascular prevention strongly recommend treating both disorders. Unfortunately, the low treatment
and control rates, combined with the high prevalence of both conditions, still contribute to the high burden of cardiovascular
disease in Western countries. In the past 5 years, many studies evaluating the benefit of combined antihypertensive and lipid-lowering
treatment on endothelial dysfunction, coronary atherosclerosis, hypertension control, and on primary and secondary prevention
of cardiovascular events have been published. In this article, we discuss and critically evaluate the available evidence on
the potential benefits of combined antihypertensive and lipid-lowering treatment. 相似文献
992.
993.
994.
Use of angiotensin-converting enzyme inhibitor therapy and dose-related outcomes in older adults with new heart failure in the community 下载免费PDF全文
Rochon PA Sykora K Bronskill SE Mamdani M Anderson GM Gurwitz JH Gill S Tu JV Laupacis A 《Journal of general internal medicine》2004,19(6):676-683
OBJECTIVE: To evaluate the dose-related benefit of angiotensin-converting enzyme (ACE) inhibitor therapy among older adults with heart failure and to evaluate whether low-dose ACE inhibitor therapy is better than none. DESIGN: Observational cohort study. SETTING: Community-dwelling older adults in Ontario, Canada. PATIENTS/PARTICIPANTS: We identified 16539 adults 66 years or older who survived 45 days following their first heart failure hospitalization discharge. MEASUREMENT AND MAIN RESULTS: Multivariate techniques including propensity scores were used to study the association between the dose of ACE inhibitor therapy dispensed and 3 outcomes: survival, survival or heart failure rehospitalization, and survival or all-cause hospitalization at 1 year of follow-up. Logistic regression models explored the association between initial dose dispensed and subsequent dose reduction or drug cessation. Overall, 10793 (65.3%) of patients were dispensed ACE inhibitor therapy, with more than a third (3935; 36.5%) initiated on low-dose therapy. Relative to dispensing of low-dose ACE inhibitor therapy, nonuse was associated with increased mortality (hazard ratio [HR], 1.12; 95% confidence interval [CI], 1.02 to 1.22). Dispensing medium-dose therapy provided a benefit similar to low-dose (HR, 0.94; CI, 0.86 to 1.03) and dispensing of high-dose therapy was associated with improved survival benefit (HR, 0.76; CI, 0.68 to 0.85). Relative to dispensing of low-dose ACE inhibitor therapy, dispensing high-dose conferred a benefit (HR, 0.87; CI, 0.80 to 0.95) on the composite outcome of 1-year mortality or heart failure hospitalization and the composite outcome of 1-year mortality or all-cause hospitalization (HR, 0.87; CI, 0.81 to 0.93). Relative to those dispensed low-dose ACE inhibitor therapy, those initially dispensed high-dose therapy were twice as likely to have their subsequent dose reduced or the therapy discontinued (odds ratio, 2.36; CI, 2.07 to 2.69). CONCLUSION: Our findings suggest that when possible, older adults should be titrated to the higher doses of ACE inhibitor therapy evaluated in clinical trials. If older adults cannot tolerate higher doses, then low-dose ACE inhibitor therapy is superior to none. High-dose ACE inhibitor therapy is not as well tolerated as lower doses. 相似文献
995.
Manabu Kinoshita Yutaka Nakaya Nagakatsu Harada Akira Takahashi Masahiro Nomura Shigenobu Bando 《Circulation journal》2002,66(7):655-658
The contraction of muscle enhances the release of bradykinin (BK) and improves glucose uptake by the muscle. Angiotensin-converting enzyme inhibitor (ACEI) slows the breakdown of BK, thus the effect of BK is augmented in the presence of ACEI. The present study investigated whether the combination of exercise (increased production of BK) and ACEI (delay in breakdown of BK) might further improve insulin sensitivity in hypertensive patients with insulin resistance (HOMA-R>1.8). Patients were assigned either to increased walking distance (Walking group) or taking 2 mg temocapril, an ACEI, daily (ACEI group) for 8 weeks. Then both interventions were given to all patients for 8 weeks (ACEI+Walking group). Blood concentrations of triglycerides were slightly lower in the ACEI+Walking group than at baseline, although there were no significant differences in total cholesterol or high density lipoprotein-cholesterol among the 2 groups. Blood glucose was not significantly different with each treatment, but blood concentrations of insulin and HOMA-R were significantly lower in the Walking and ACEI groups compared with the Control group. The combination of walking and ACEI further lowered blood concentrations of insulin and HOMA-R, which suggests that this treatment is beneficial for hypertensive patients with insulin resistance. 相似文献
996.
Topical Nifedipine With Lidocaine Ointment <Emphasis Type="Italic">vs.</Emphasis> Active Control for Treatment of Chronic Anal Fissure 总被引:1,自引:1,他引:1
Perrotti P Bove A Antropoli C Molino D Antropoli M Balzano A De Stefano G Attena F 《Diseases of the colon and rectum》2002,45(11):1468-1475
PURPOSE: Chronic anal fissure may be treated by chemical or surgical sphincterotomy. The aim of this study was to test the efficacy of local application of nifedipine and lidocaine ointment in healing chronic anal fissure. METHODS: The study was performed according to a prospective, randomized, double-blind design. One hundred ten patients who gave informed consent were recruited. They received a clinical examination, a questionnaire to evaluate symptoms and pain, anorectal manometry, and anoscopy. Healing of anal fissure at Day 42 of therapy was defined as the primary efficacy variable of the study. Patients treated with nifedipine (n = 55) used topical 0.3 percent nifedipine and 1.5 percent lidocaine ointment every 12 hours for 6 weeks. The control group (n = 55) received topical 1.5 percent lidocaine and 1 percent hydrocortisone acetate ointment during therapy. Anal pressures were measured by recording resting and maximal voluntary contraction pressures at baseline and at Day 21. Long-term outcomes were determined after a median follow-up of 18 months. RESULTS: Healing of chronic anal fissure was achieved after 6 weeks of therapy in 94.5 percent of the nifedipine-treated patients (P < 0.001) as opposed to 16.4 percent of the controls. Mean anal resting pressure decreased from a mean value +/- standard deviation of 47.2 +/- 14.6 to 42 +/- 12.4 mmHg in the nifedipine group. This represents a mean reduction of 11 percent (P = 0.002). Changes of maximal voluntary contraction in nifedipine-treated patients were not significant. No changes in mean anal resting pressure and maximal voluntary contraction were observed in the control group. We did not observe any systemic side effect in patients treated with nifedipine. After the blinding was removed, recurrence of the fissure was observed in 3 of 52 patients in the nifedipine group within 1 year of treatment, and 2 of these patients healed with an additional course of topical nifedipine and lidocaine ointment. CONCLUSIONS: Our study clearly demonstrates that the therapeutic use of topical nifedipine and lidocaine ointment should be extended to the conservative treatment of chronic anal fissure. 相似文献
997.
The new histologic classification of chronic rhinosinusitis 总被引:2,自引:0,他引:2
Two histologic patterns of disease are found in chronic rhinosinusitis. The first is dominated by eosinophilia and polypoid
changes. Glandular hyperplasia and hypertrophy characterize the second. We present the evidence supporting the existence of
these two patterns of disease and link these histologic patterns to the larger pathophysiologic processes that drive them.
This histologic classification should be acknowledged both in the clinical setting and in laboratory research of chronic rhinosinusitis. 相似文献
998.
Minireview: recent developments in the regulation of glucose transporter-4 traffic: new signals, locations, and partners 总被引:8,自引:0,他引:8
Glucose transporter (GLUT) 4 is the major glucose transporter of muscle and adipose cells, exquisitely regulated by insulin through posttranslational events. Twenty years after the seminal observations that GLUT4 levels rapidly rise at the plasma membrane (PM) and drop in endomembranes in response to an acute insulin challenge, we are still mapping the intracellular traffic of the transporter and the regulatory events that insulin unleashes. Newly synthesized GLUT4 enters an insulin-responsive compartment aided by GGA2 (an Arf-binding protein). In cultured adipocytes and myocytes, GLUT4 concentrates in a perinuclear pole through participation of microtubules and the EHD1 Eps15 homology domain-containing protein 1. In the absence of stimuli, GLUT4 distributes between recycling endosomes and the insulin-responsive compartment. A handful of proteins that bind to GLUT4 appear to regulate its half-life (e.g. Ubc9) and tethering within endomembranes (e.g. TUG). Insulin-derived signals promote not only GLUT4 mobilization toward the PM but also its traffic between endosomal compartments and internalization from the PM. Class IA phosphatidylinositol (PI) 3-kinase plays a pivotal role at several steps of GLUT4 mobilization. The PI 3-kinase --> atypical PKC and --> Akt/PKB --> AS160 signaling cascades are major regulators of GLUT4 exocytosis aided by small GTPases. At the cell periphery, GLUT4-containing vesicles tether, dock, and fuse with the PM assisted by the exocyst complex followed by engagement of a soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex [with vesicle-associated membrane protein (VAMP)2 as the vesicular (v)-SNARE and soluble NSF-attachment protein (SNAP)23 and syntaxin4 as target (t)-SNAREs] regulated by the accessory proteins Munc18c, Synip and Tomosyn. Vesicle tethering and fusion are regulated by insulin through input from class IA PI 3-kinase. 相似文献
999.
Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis 总被引:5,自引:0,他引:5
Nakamura M Shimizu-Yoshida Y Takii Y Komori A Yokoyama T Ueki T Daikoku M Yano K Matsumoto T Migita K Yatsuhashi H Ito M Masaki N Adachi H Watanabe Y Nakamura Y Saoshiro T Sodeyama T Koga M Shimoda S Ishibashi H 《Journal of hepatology》2005,42(3):386-392
BACKGROUND/AIMS: The presence of antibodies to the 210-kDa glycoprotein of the nuclear pore complex (gp210) is highly indicative of primary biliary cirrhosis (PBC). However, the significance of anti-gp210 antibody titers for monitoring PBC remains unresolved. METHODS: We used an ELISA with a gp210 C-terminal peptide as an antigen to assess serum antibody titers in 71 patients with PBC. RESULTS: Patients were classified into three groups: Group A in whom anti-gp210 titers were sustained at a high level, Group B in whom anti-gp210 status changed from positive to negative under ursodeoxycholic acid (UDCA) therapy, Group C in whom anti-gp210 antibodies were negative at the time of diagnosis. The rate of progression to end-stage hepatic failure was significantly higher in group A (60%) as compared to groups B (0%) and C (4.2%). The sustained antibody response to gp210 was closely associated with the severity of interface hepatitis. The significance of anti-gp210 antibody was confirmed by National Hospital Organization Study Group for Liver Disease in Japan. CONCLUSIONS: The serial quantitation of serum anti-gp210-C-terminal peptide antibodies is useful for monitoring the effect of UDCA and for the early identification of patients at high risk for end-stage hepatic failure. 相似文献
1000.
Hui-Zhen Zhang Jin-Jian Wei Kannekanti Vijaya Kumar Syed Rasheed Cheng-He Zhou 《Medicinal chemistry research》2015,24(1):182-196
A series of novel d-glucose-derived 1,2,3-triazoles have been synthesized in excellent yields via Cu(I)-catalyzed 1,3-dipolar cycloaddition by using methyl α-d-glucopyranoside as starting material. All the new compounds were confirmed by 1H NMR, 13C NMR, IR, MS, and HRMS spectra, and their antimicrobial activities were screened against Gram-Positive, Gram-Negative bacteria, and fungi. Bioactive assay manifested that some of the synthesized glucose-derived 1,2,3-triazoles exhibited good antibacterial and antifungal activities. Notably, compound 5k gave the most potent efficiency with MIC50 value of 6 µM against Candida albicans, which was nine-fold more active than the reference drug Fluconazole. It also exhibited good antibacterial activity against Escherichia coli with the MIC50 value of 10.8 µM compared to Chloramphenicol while the corresponding hydrochloride 4k revealed remarkable inhibitory against Bacillus subtilis with an MIC50 value of 11 µM. 相似文献